Breast Cancer
GS-US-595-6184: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)
- Details
ClinicalTrials.gov ID:
NCT05633654
Diagnosis Type:
NA
USOR Number:
- Address
,
P: